Ani Pharmaceuticals director Thoma sells $71,530 in shares

Jeanne Thoma, a director at ANI Pharmaceuticals Inc. (ANI), sold 1,000 shares of the company's common stock on September 11, 2026. She executed the trade at a price of $71.53 per share, resulting in a total of $71,530. This transaction was carried out in accordance with a Rule 10b5-1 trading plan that Ms. Thoma had previously adopted on June 12, 2026. After the sale, she still held 26,762 shares of ANI Pharmaceuticals common stock.

ANI Pharmaceuticals shares were trading near their 52-week low of $69.58 at the time of the sale, currently priced at $70.40. InvestingPro analysis suggests that the stock is undervalued at these levels. The company is known for its strong financial health, and InvestingPro provides additional exclusive insights and a comprehensive Pro Research Report for further analysis.

ANI Pharmaceuticals recently reported its second-quarter 2026 results, which surpassed expectations. Adjusted earnings per share were $2.21, exceeding expectations of $2.03. The company also achieved record revenue of $266 million, surpassing the forecasted $262.14 million. Despite the strong performance, analysts have varied opinions on the company's outlook.

Guggenheim revised its price target for ANI Pharmaceuticals from $124 to $119, maintaining a Buy rating, while Canaccord Genuity adjusted its target from $91 to $90, maintaining a Hold rating due to earnings miss and underperformance of Cortrophin, a key growth driver. The company reduced its full-year guidance for Cortrophin by $20 million to $25 million, although it remains optimistic about the product's growth potential.

In summary, the mixed reactions from analysts regarding ANI Pharmaceuticals' outlook were evident in the recent developments. This article was AI-generated and reviewed by an editor.